What are the first-line and second-line treatment options for bacterial prostatitis in an adult male?

Treatment of Infectious Prostatitis

For acute bacterial prostatitis, initiate broad-spectrum antibiotics immediately—fluoroquinolones (ciprofloxacin or levofloxacin) are first-line for 2-4 weeks, with alternatives including intravenous ceftriaxone plus doxycycline or piperacillin-tazobactam for severe cases; for chronic bacterial prostatitis, use fluoroquinolones for a minimum of 4 weeks (up to 12 weeks may be needed). 1, 2

Acute Bacterial Prostatitis (ABP)

Primary (First-Line) Treatment

Outpatient Management:

• Fluoroquinolones are the cornerstone of therapy 2, 3:
  • Ciprofloxacin 500-750 mg orally twice daily for 2-4 weeks
  • Levofloxacin 500 mg orally once daily for 2-4 weeks
  • Success rate: 92-97% when prescribed appropriately 2

Inpatient/Severe Cases: Consider hospitalization and IV antibiotics if the patient has 4:

• Systemic illness (fever >38.5°C, rigors, hemodynamic instability)
• Urinary retention requiring catheterization
• Unable to tolerate oral intake
• Risk factors for antibiotic resistance
• Immunocompromised status

IV regimens 2, 4:

• Ceftriaxone 1-2 g IV daily PLUS doxycycline 100 mg twice daily
• Piperacillin-tazobactam 4.5 g IV every 6-8 hours
• Ciprofloxacin 400 mg IV every 12 hours

Diagnostic Approach Before Treatment

The 2024 EAU guidelines provide clear diagnostic steps 1:

• Do NOT perform prostatic massage in ABP (strong recommendation—risk of bacteremia)
• Obtain midstream urine culture to guide therapy (weak recommendation)
• Check urine dipstick for nitrites and leukocytes
• Obtain blood cultures and complete blood count in febrile patients
• Consider transrectal ultrasound only if prostatic abscess is suspected

Key Pathogen Information

Enterobacterales (E. coli, Klebsiella, Pseudomonas) cause 80-97% of cases 1, 2

---

Chronic Bacterial Prostatitis (CBP)

Primary (First-Line) Treatment

Fluoroquinolones remain first-line 1, 3, 5:

• Minimum 4 weeks of therapy required (may extend to 12 weeks for refractory cases)
• Levofloxacin 500 mg orally once daily
• Ciprofloxacin 500 mg orally twice daily
• Cure rate approximately 70% with fluoroquinolones 5

Important distinction: CBP requires significantly longer treatment than ABP due to poor antibiotic penetration into chronically infected prostatic tissue and biofilm formation 3, 6

Secondary (Second-Line) Treatment

When fluoroquinolones fail or resistance is documented 3, 5:

1. Trimethoprim-sulfamethoxazole (TMP-SMX)

   • 160/800 mg orally twice daily for 4-12 weeks
   • Use only if pathogen susceptibility confirmed

2. Doxycycline

   • 100 mg orally twice daily for 4-12 weeks
   • Particularly useful for atypical organisms (Chlamydia, Mycoplasma) 1

3. Fosfomycin (emerging option for multidrug-resistant organisms)

   • Useful for resistant pathogens 3, 6
   • Dosing varies; typically 3 g every 48-72 hours

4. Chronic suppressive therapy if recurrent infections persist 5:

   • Low-dose TMP-SMX, fluoroquinolone, or nitrofurantoin
   • Used when curative therapy fails but symptoms can be controlled

Diagnostic Approach for CBP

The 2024 EAU guidelines specify 1:

• Perform Meares-Stamey 4-glass test or modified 2-glass test (strong recommendation)
• Test for atypical pathogens (Chlamydia trachomatis, Mycoplasma species) (weak recommendation)
• Do NOT rely on ejaculate analysis alone

The 4-glass test differentiates prostatic from urethral infection by comparing bacterial counts in:

1. First-void urine (urethral)
2. Midstream urine (bladder)
3. Expressed prostatic secretions (prostate)
4. Post-massage urine (prostate)

---

Critical Clinical Pitfalls

Common Mistakes to Avoid

1. Inadequate treatment duration in CBP: Using ABP duration (2-4 weeks) for CBP leads to high recurrence rates. CBP requires minimum 4 weeks, often 6-12 weeks 3, 6

2. Performing prostatic massage in ABP: This is contraindicated due to bacteremia risk 1

3. Missing prostatic abscess: If fever persists >48-72 hours on appropriate antibiotics, obtain transrectal ultrasound or CT to rule out abscess requiring drainage 1, 4

4. Ignoring urinary retention: Check post-void residual; retention requires catheterization (preferably suprapubic to avoid urethral trauma) 4

5. Overlooking atypical organisms in CBP: Up to 74% are gram-negative, but atypical organisms (Chlamydia, Mycoplasma) require different antibiotics 1, 3

When to Escalate Care

• Urosepsis: Requires ICU involvement, source control (drainage of obstruction/abscess), and broad-spectrum IV antibiotics 1
• Prostatic abscess: Needs urological drainage (transrectal or transurethral) plus prolonged antibiotics 4
• Multidrug-resistant organisms: Consider infectious disease consultation for alternative agents (fosfomycin, carbapenems) 3, 6

---

Pathogen-Specific Considerations

Enterobacterales (most common) 1, 2:

• First-line: Fluoroquinolones
• Resistance increasing—always obtain cultures

Atypical organisms (Chlamydia, Mycoplasma) 1:

• Doxycycline 100 mg twice daily for 4+ weeks
• Alternative: Azithromycin (though less effective for prostatitis)

Multidrug-resistant organisms 3, 6:

• Fosfomycin (repurposed agent showing promise)
• Consider direct intraprostatic antibiotic injection (investigational)
• Surgical debridement of infected tissue in refractory cases

---

Treatment Algorithm Summary

For ABP:

1. Mild-moderate outpatient → Oral fluoroquinolone × 2-4 weeks
2. Severe/systemic → IV antibiotics (ceftriaxone + doxycycline OR piperacillin-tazobactam) → transition to oral fluoroquinolone to complete 2-4 weeks total
3. If no improvement in 48-72 hours → Image for abscess

For CBP:

1. First episode → Fluoroquinolone × 4-6 weeks minimum
2. Recurrence/failure → TMP-SMX or doxycycline × 6-12 weeks (if susceptible)
3. Multiple recurrences → Consider fosfomycin, chronic suppression, or urological consultation for surgical options
4. Always test for atypical organisms if standard therapy fails

The evidence strongly supports fluoroquinolones as first-line for both ABP and CBP, with the critical distinction being treatment duration 1, 2, 3. The 2024 EAU guidelines provide the most current framework, emphasizing proper microbiological diagnosis and pathogen-directed therapy 1.